Overview

Gender

male

David has spent the past twenty years developing novel drugs for global registration; during that time he has focused his efforts on non-absorbed, non-systemic new chemical entities.

He began his career at Arthur D. Little (ADL), where he was a senior consultant and study director for over a hundred pharmacology and GLP toxicology studies in a wide variety of therapeutic areas. Since ADL, David has spent his career working for start-up and small pharmaceutical companies.

Most notably, David was Vice President of Preclinical Research and Development at GelTex Pharmaceuticals, where he was integral in the development and approval of two non-absorbed drugs: RenaGel and WelChol.

Most recently, David was Vice President of Drug Development for Trine Pharmaceuticals, where he was developing a novel non-systemic therapeutic for the treatment of IBS. David has filed numerous INDs, met with regulatory agencies around the world, and filed two approved NDAs.

David received a Ph.D. in Pharmacology from Boston University School of Medicine; a M.S. in Toxicology from Albany Medical College; and a B.A. in Biology from the University of Pennsylvania.